Mayne Pharma (ASX:MYX)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Mayne Pharma.
RELATED STOCKHEAD STORIES
Health Check: Mayne Pharma shareholders back $600m ‘phantom’ takeover offer
Health Check: A pancreatic cancer ‘cure’ has been elusive, but Amplia may have cracked the nut
Scott Power: ASX health stocks dip but it was a good news week for EMVision
Health Check: Medical device makers Trump drug developers in volatile US healthcare climate
Health Check: Whether stoic or simply too poor, Australians spurn GP visits
Scott Power: ASX health stocks rise with capital raisings in full swing
Closing Bell: ASX breaks to new 50-day high; gold stocks surge
Health Check: Mayne Pharma shares tumble after suitor threatens to walk over ‘adverse events’
Lunch Wrap: ASX marches on despite war jitters; Nufarm and Mayne plummet
Health Check: Biotechs obey the Three Commandments of life sciences
Health Check: In rude health, Alcidion shrugs off UK National Health Service reforms
Lunch Wrap: ASX spirals down 1pc as Wall Street panics again; gold goes through the roof
Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much
